Cytokinetics (CYTK) shared an update on its hypertrophic cardiomyopathy franchise at the Citigroup Biopharma Back to School Summit on Wednesday, September 9, 2026, projecting continued commercial momentum for its drug aficamten — marketed as MYQORZO.
The company reported that MYQORZO achieved 40% new-to-brand share by the end of the second quarter, signaling rapid uptake among prescribers treating obstructive HCM. CEO Robert Blum called the launch "a great start" that continues to exceed expectations, noting the market is embracing the drug for the properties engineered into it.
Commercial expansion beyond the United States is advancing. Germany launched MYQORZO in summer 2026, the United Kingdom is targeted for a Q4 debut, and additional major European markets are expected in 2027, according to the company's presentation.
On the clinical front, Cytokinetics provided an update on its broader cardiovascular pipeline. The COMET-HF confirmatory trial, which is studying aficamten in heart failure patients with reduced ejection fraction, is enrolling approximately 2,000 participants and is expected to complete enrollment in 2027, with a possible data readout in 2028.
Separately, the GALACTIC-HF trial enrolled more than 8,000 patients with non-obstructive HCM, a population that Dr. Dan Jacoby, head of clinical research, estimated represents a significant untapped market given that physicians typically see 10 to 12 NHCM patients in their practices. Clinical history with aficamten has utilized titration dose steps of 5, 10, 15, and 20 milligrams.
Financially, Cytokinetics generated $67.7 million in revenue over the trailing twelve months and maintains liquid assets exceeding its short-term obligations by more than six times. Shares closed at $75.35, up $2.63 or 3.62%, with pre-market trading at $75.97. Analyst consensus rates the stock a Strong Buy, with price targets ranging from $85 to $146.
Other pipeline programs referenced during the presentation include the ACACIA-HCM, SEQUOIA-HCM, and MAPLE-HCM trials.
